[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564264":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":31,"centralContacts":32,"locations":38,"responsibleParty":167,"collaborators":31,"id":169,"slug":31,"hasResults":170,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":31,"eligibilityCriteria":173,"healthyVolunteers":170,"sex":174,"minAge":175,"maxAge":31,"enrollmentInfo":176,"targetDuration":31,"studyType":179,"phases":180,"briefSummary":182,"conditions":183,"keywords":191,"overallStatus":41,"whyStopped":31,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":215},{"fullName":5,"class":6},"Arcellx, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"anito-cel","EXPERIMENTAL","Single dose of anito-cel cells infused intravenously",[13,14],"Biological: anito-cel","Drug: Standard Lymphodepletion regimen",[16,23],{"type":17,"name":9,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","Anitocabtagene autoleucel BCMA directed CAR T-cell therapy using a novel, synthetic binding domain, called a D-Domain",[9],[21,22],"anitocabtagene autoleucel","CART-ddBCMA",{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Standard Lymphodepletion regimen","Standard lymphodepletion regimen subject receive 5 days prior to CAR T infusion",[9],[29,30],"Cyclophosphamide","Fludarabine",null,[33],{"name":34,"role":35,"phone":36,"phoneExt":31,"email":37},"Clinical Information","CONTACT","240-327-0379","clinical@arcellx.com",[39,52,61,70,80,90,100,109,118,128,138,148,158],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":31},"UCLA Medical Center","RECRUITING","Los Angeles","California","90095","United States",{"type":47,"coordinates":48},"Point",[49,50],-118.24368,34.05223,{"lat":50,"lon":49},{"facility":53,"status":41,"city":54,"state":43,"zip":55,"country":45,"cosmosGeoPoint":56,"geoPoint":60,"contacts":31},"University of California, Irvine","Orange","92602",{"type":47,"coordinates":57},[58,59],-117.85311,33.78779,{"lat":59,"lon":58},{"facility":62,"status":41,"city":63,"state":43,"zip":64,"country":45,"cosmosGeoPoint":65,"geoPoint":69,"contacts":31},"Stanford Hospital","Palo Alto","94305",{"type":47,"coordinates":66},[67,68],-122.14302,37.44188,{"lat":68,"lon":67},{"facility":71,"status":41,"city":72,"state":73,"zip":74,"country":45,"cosmosGeoPoint":75,"geoPoint":79,"contacts":31},"University of South Florida - Carol and Frank Morsani Center of Advanced Healthcare","Tampa","Florida","33612",{"type":47,"coordinates":76},[77,78],-82.45843,27.94752,{"lat":78,"lon":77},{"facility":81,"status":41,"city":82,"state":83,"zip":84,"country":45,"cosmosGeoPoint":85,"geoPoint":89,"contacts":31},"Karmanos Cancer Institute","Detroit","Michigan","48201",{"type":47,"coordinates":86},[87,88],-83.04575,42.33143,{"lat":88,"lon":87},{"facility":91,"status":41,"city":92,"state":93,"zip":94,"country":45,"cosmosGeoPoint":95,"geoPoint":99,"contacts":31},"University of Minnesota Delaware Clinical Research Unit","Minneapolis","Minnesota","55414",{"type":47,"coordinates":96},[97,98],-93.26384,44.97997,{"lat":98,"lon":97},{"facility":101,"status":41,"city":102,"state":93,"zip":103,"country":45,"cosmosGeoPoint":104,"geoPoint":108,"contacts":31},"Mayo Clinic","Rochester","55905",{"type":47,"coordinates":105},[106,107],-92.4699,44.02163,{"lat":107,"lon":106},{"facility":110,"status":41,"city":111,"state":111,"zip":112,"country":45,"cosmosGeoPoint":113,"geoPoint":117,"contacts":31},"Columbia University Irving Medical Center","New York","10032",{"type":47,"coordinates":114},[115,116],-74.00597,40.71427,{"lat":116,"lon":115},{"facility":119,"status":41,"city":120,"state":121,"zip":122,"country":45,"cosmosGeoPoint":123,"geoPoint":127,"contacts":31},"Ohio State University","Columbus","Ohio","43221",{"type":47,"coordinates":124},[125,126],-82.99879,39.96118,{"lat":126,"lon":125},{"facility":129,"status":41,"city":130,"state":131,"zip":132,"country":45,"cosmosGeoPoint":133,"geoPoint":137,"contacts":31},"Oregon Health & Science University (OHSU)","Portland","Oregon","97239",{"type":47,"coordinates":134},[135,136],-122.67621,45.52345,{"lat":136,"lon":135},{"facility":139,"status":41,"city":140,"state":141,"zip":142,"country":45,"cosmosGeoPoint":143,"geoPoint":147,"contacts":31},"Temple University Hospital","Philadelphia","Pennsylvania","19140",{"type":47,"coordinates":144},[145,146],-75.16362,39.95238,{"lat":146,"lon":145},{"facility":149,"status":41,"city":150,"state":151,"zip":152,"country":45,"cosmosGeoPoint":153,"geoPoint":157,"contacts":31},"UT Southwestern Medical Center","Dallas","Texas","75390",{"type":47,"coordinates":154},[155,156],-96.80667,32.78306,{"lat":156,"lon":155},{"facility":159,"status":41,"city":160,"state":151,"zip":161,"country":45,"cosmosGeoPoint":162,"geoPoint":166,"contacts":31},"Houston Methodist Hospital","Houston","77030",{"type":47,"coordinates":163},[164,165],-95.36327,29.76328,{"lat":165,"lon":164},{"type":168,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100564264",false,"NCT06626919","A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases","Inclusion Criteria:\n\n* Subject must be 18 years of age or older\n* Must have MGFA clinical classification Grades 2-4A at time of screening\n* Subject must have clinically active disease and requiring ongoing therapy for GMG\n* MG-ADL score 6 and QMG score \\>10 at screening\n* GMG specific autoantibodies must be above the reference laboratory ULN\n\nExclusion Criteria:\n\n* Subject is pregnant or breastfeeding\n* Treatment with Anti-CD20 agents, calcineurin inhibitors, FcRN inhibitors, azathioprine, mycophenolate mofetil, methotrexate, or cyclophosphamide within the specified time frame prior to leukapheresis or prior to anito-cel infusion\n* Previous treatment with any gene therapy, chimeric antigen receptor therapy or T cell engager\n* Previous thymectomy within 6 months of screening\n* Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator","ALL","18 Years",{"count":177,"type":178},30,"ESTIMATED","INTERVENTIONAL",[181],"PHASE1","A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.",[184,185,186,187,188,189,190],"Muscular Diseases","Neuromuscular Manifestations","Autoimmune","Autoimmune Diseases","Autoimmune Diseases of the Nervous System","Myasthenia Gravis","Muscle Weakness",[192,193,194,195,196,197,198,199,189,200,201,202,203,204,205,21],"ARC-311","CART","CAR-T","BCMA","Anito-cel","Generalized Myasthenia Gravis","gMG","MG","non-oncology plasma cell","autoimmune","auto-antibody","chimeric antigen receptor","D-Domain chimeric antigen receptor","B-cell maturation antigen (BCMA)","2026-02-24",{"date":208,"type":209},"2026-02-25","ACTUAL",{"date":211,"type":209},"2025-04-30",{"date":213,"type":178},"2028-04",{"name":5,"class":6},13]